ARA-290

ARA-290 (cibinetide) is an 11-residue synthetic peptide modeled on a region of erythropoietin. It is supplied for laboratory research on the EPOR-CD131 receptor complex.

Research applications

ARA-290 is used in cell and animal systems to study signaling through the EPOR-CD131 receptor complex. Typical readouts include cytokines such as IL-6, TNF-alpha and IL-12, NF-kappaB markers and macrophage activation. Other designs use endothelial progenitor survival and migration assays, small-fiber nerve measures, or wound-closure and tissue-repair scoring. All of this is laboratory research.

Pathway and mechanistic context

ARA-290 is described as engaging the EPO receptor and beta common receptor heterocomplex, not the classical EPO receptor homodimer. Reported downstream signaling involves JAK2, PI3K/Akt and NF-kappaB pathways. Further studies examine macrophage cytokine release, apoptotic signaling under stress, and possible interaction with TRPV1 channels.

Preclinical summary

Animal and cell studies have examined ARA-290 or cibinetide in endothelial progenitor function, macrophage activation, experimental colitis and transplant-related tissue injury. Other work looked at wound healing in diabetic mice and a lupus mouse model. These are laboratory and model findings only.

Form and analytical testing

Supplied as a lyophilized powder. Identity and purity are normally confirmed by HPLC and mass spectrometry. Refer to the Certificate of Analysis for the lot you receive.

References

1. M. Brines et al. , "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes," Mol. Med. Camb. Mass , vol. 20, pp. 658–666, Mar. 2015, doi: 10.2119/molmed.2014.00215. Source
2. O. E. O'Leary et al. , "The vasoreparative potential of endothelial colony-forming cells in the ischemic retina is enhanced by cibinetide, a non-hematopoietic erythropoietin mimetic," Exp. Eye Res. , vol. 182, pp. 144–155, 2019, doi: 10.1016/j.exer.2019.03.001.
3. G. Hache et al. , "ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability," Shock Augusta Ga , vol. 46, no. 4, pp. 390–397, 2016, doi: 10.1097/SHK.0000000000000606.
4. M. Watanabe et al. , "A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets," Transplantation , vol. 100, no. 3, pp. 554–562, Mar. 2016, doi: 10.1097/TP.0000000000001026.
5. M. Nairz et al. , "Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis," Sci. Rep. , vol. 7, no. 1, p. 13012, 12 2017, doi: 10.1038/s41598-017-13046-3.
6. A. Bitto et al. , "Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes," Biochim. Biophys. Acta BBA - Mol. Basis Dis. , vol. 1864, no. 2, pp. 632–639, Feb. 2018, doi: 10.1016/j.bbadis.2017.12.006.

Peptides are shipped lyophilized (freeze-dried), a state that keeps them stable in transit. Keep vials cold and away from light on arrival.

• Short term: refrigeration below 4°C (39°F) is generally suitable for lyophilized material held for days to months.
• Long term: a freezer at -80°C (-112°F) is preferred for storage over several months or years.
• After reconstitution: keep the vial refrigerated. Reconstituted material is generally kept for up to 30 days.